Scholarlink

Background <p>Despite global malaria control efforts, malaria continues to cause approximately 241–249 million cases and over 600,000 deaths annually. Ivermectin, a broad-spectrum antiparasitic drug with endectocidal activity against mosquitoes feeding on treated hosts, has been proposed as a potential malaria vector-control intervention.</p> Objective <p>To systematically evaluate the effectiveness of ivermectin in reducing malaria transmission outcomes in adult populations, including malaria incidence, prevalence, mosquito mortality, and safety outcomes.</p> Methods <p>Following PRISMA 2020 guidelines, we included randomized controlled trials (RCTs) and cluster-RCTs evaluating ivermectin compared with placebo, standard care, or non-ivermectin controls in adult populations. Outcomes included malaria incidence, prevalence, mosquito mortality, and adverse events.</p> Results <p>Ten randomized trials involving 63,192 participants were included. Community-level analyses showed no significant reduction in malaria prevalence, with very wide confidence intervals reflecting substantial imprecision. Entomological trials demonstrated increased mosquito mortality following ivermectin exposure (RR 1.89; 95% CI 1.26–2.83), although heterogeneity was substantial (I<sup>2</sup> &gt; 97%). Across studies, ivermectin was generally well tolerated, with no significant increase in adverse events.</p> Conclusions <p>Current evidence does not demonstrate consistent reductions in malaria incidence or prevalence with ivermectin administration, although laboratory and experimental studies suggest mosquitocidal effects. Further large, well-designed cluster-randomized trials are required to determine whether ivermectin can contribute to malaria control strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of ivermectin for malaria vector control: a systematic review and meta-analysis of randomized clinical trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月31日

查看全文
  • Shrouk Ramadan,
  • Ahmed Talkhan,
  • Anas Mansour,
  • Dua’a Kanaan,
  • Ahmed Noureldeen Abbas,
  • Abdelrahman Awad,
  • Omer Bin Sahel,
  • Lara Hamzeh Hamzeh,
  • Ayat Alfaki,
  • Mohamed Hany,
  • Mohamed Elnouty,
  • Mohammed Hammad Jaber Amin

摘要

Background

Despite global malaria control efforts, malaria continues to cause approximately 241–249 million cases and over 600,000 deaths annually. Ivermectin, a broad-spectrum antiparasitic drug with endectocidal activity against mosquitoes feeding on treated hosts, has been proposed as a potential malaria vector-control intervention.

Objective

To systematically evaluate the effectiveness of ivermectin in reducing malaria transmission outcomes in adult populations, including malaria incidence, prevalence, mosquito mortality, and safety outcomes.

Methods

Following PRISMA 2020 guidelines, we included randomized controlled trials (RCTs) and cluster-RCTs evaluating ivermectin compared with placebo, standard care, or non-ivermectin controls in adult populations. Outcomes included malaria incidence, prevalence, mosquito mortality, and adverse events.

Results

Ten randomized trials involving 63,192 participants were included. Community-level analyses showed no significant reduction in malaria prevalence, with very wide confidence intervals reflecting substantial imprecision. Entomological trials demonstrated increased mosquito mortality following ivermectin exposure (RR 1.89; 95% CI 1.26–2.83), although heterogeneity was substantial (I2 > 97%). Across studies, ivermectin was generally well tolerated, with no significant increase in adverse events.

Conclusions

Current evidence does not demonstrate consistent reductions in malaria incidence or prevalence with ivermectin administration, although laboratory and experimental studies suggest mosquitocidal effects. Further large, well-designed cluster-randomized trials are required to determine whether ivermectin can contribute to malaria control strategies.